MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)

Clinical Trial ID NCT02088112

PubWeight™ 6.88‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02088112

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
2 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
3 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
4 Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med 2016 0.83
5 FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. Cell Death Discov 2015 0.80
6 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
7 A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow. Cancer Discov 2014 0.77
8 Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther 2016 0.75
Next 100